Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
AIDS and Behavior
Erschienen in: AIDS and Behavior 4/2017

13.10.2016 | Original Paper

Prevalence and Predictors of Substance Use Disorders Among HIV Care Enrollees in the United States

verfasst von: Bryan Hartzler, Julia C. Dombrowski, Heidi M. Crane, Joseph J. Eron, Elvin H. Geng, W. Christopher Mathews, Kenneth H. Mayer, Richard D. Moore, Michael J. Mugavero, Sonia Napravnik, Benigno Rodriguez, Dennis M. Donovan

Erschienen in: AIDS and Behavior | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Prior efforts to estimate U.S. prevalence of substance use disorders (SUDs) in HIV care have been undermined by caveats common to single-site trials. The current work reports on a cohort of 10,652 HIV-positive adults linked to care at seven sites, with available patient data including geography, demography, and risk factor indices, and with substance-specific SUDs identified via self-report instruments with validated diagnostic thresholds. Generalized estimating equations also tested patient indices as SUD predictors. Findings were: (1) a 48 % SUD prevalence rate (between-site range of 21–71 %), with 20 % of the sample evidencing polysubstance use disorder; (2) substance-specific SUD rates of 31 % for marijuana, 19 % alcohol, 13 % methamphetamine, 11 % cocaine, and 4 % opiate; and (3) emergence of younger age and male gender as robust SUD predictors. Findings suggest high rates at which SUDs occur among patients at these urban HIV care sites, detail substance-specific SUD rates, and identify at-risk patient subgroups.
Literatur
1.
Moore RD, Bartlett JG. Dramatic decline in the HIV-1 RNA level over calendar time in a large urban HIV practice. Clin Infect Dis. 2011;53:600–4.CrossRefPubMedPubMedCentral
2.
Althoff KN, Buchacz K, Hall HI, et al. U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons. Ann Intern Med. 2012;157:325–35.CrossRefPubMedPubMedCentral
3.
Gardner EM, McLees MP, Steiner JF, del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793–800.CrossRefPubMedPubMedCentral
4.
Mugavero MJ, Amico KR, Horn T, Thompson MA. The state of engagement in HIV care in the United States: from cascade to continuum to control. Clin Infect Dis. 2013;57(8):1164–71.CrossRefPubMed
5.
McLellan AT, Woodworth AM. The affordable care act and treatment for ‘substance use disorders’: implications of ending segregated behavioral healthcare. J Subst Abuse Treat. 2014;46:541–5.CrossRefPubMed
6.
McCance-Katz EF, Rabiner CA, Rivers JLA. The affordable care act: implementation and implications for addiction specialty care. The American Journal on Addictions. 2014;23:429–30.CrossRefPubMed
7.
Denis CM, Gelernter J, Hart AB, Kranzler HR. Inter-observer reliability of DSM-5 substance use disorders. Drug Alcohol Depend. 2015;153:229–35.CrossRefPubMedPubMedCentral
8.
Hall HI, Holtgrave DR, Tang T, Rhodes P. HIV transmission in the United States: considerations of viral load, risk behavior, and health disparities. AIDS Behav. 2013;17:1632–6.CrossRefPubMed
9.
Dieffenbach WW, Fauci AS. Universal voluntary testing and treatment for prevention of HIV transmission. JAMA. 2009;301:2380–2.CrossRefPubMed
10.
Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: A mathematical model. Lancet. 2009;373:48–57.CrossRefPubMed
11.
Giordano TP, Visnegarwala F, White ACJ, Troisi CL, Frankowski RF, Hartman CM, et al. Patients referred to an urban HIV clinic frequently fail to establish care: Factors predicting failure. AIDS Care. 2005;17(6):773–83.CrossRefPubMed
12.
Meyer JP, Althoff AL, Altice FL. Optimizing care for HIV-infected people who use drugs: evidcence-based approaches to overcoming healthcare disparities. Clin Infect Dis. 2013;57(9):1309–17.CrossRefPubMedPubMedCentral
13.
DeLorenze GN, Weisner C, Tsai AL, Satre DD, Quesenberry CP Jr. Excess mortality among HIV-infected patients diagnosed with substance use dependence or abuse receiving care in a fully integrated medical care program. Alcohol Clin Exp Res. 2011;35(2):203–10.CrossRefPubMed
14.
Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17(5):377–81.CrossRefPubMedPubMedCentral
15.
Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. J Acquir Immune Defic Syndr. 2006;43(4):411–7.CrossRefPubMedPubMedCentral
16.
Reback CJ, Larkins S, Shoptaw S. Methamphetamine abuse as a barrier to HIV medication adherence among gay and bisexual men. AIDS Care. 2003;15(6):775–85.CrossRefPubMed
17.
Pence BW, Miller WC, Gaynes BN, Eron JJ Jr. Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;44(2):159–66.CrossRefPubMed
18.
King WD, Larkins S, Hucks-Ortiz C, et al. Factors associated with HIV viral load in a respondent driven sample in Los Angelos. AIDS Behav. 2009;13(1):145–53.CrossRefPubMed
19.
Giordano TP, Gifford AL, White ACJ, et al. Retention in care: a challenge to survival with HIV infection. Clin Infect Dis. 2007;44:1493–9.CrossRefPubMed
20.
Torian LV, Wiewel EW. Continuity of HIV-related medical care, New York City, 2005–2009: do patients who initiate care stay in care? AIDS, Patient Care, STDs. 2011;25:79–88.CrossRef
21.
Hall HI, Gray KM, Tang T, Li J, Shouse L, Mermin J. Retention in care of adults and adolescents living with HIV in 13 U.S. areas. J Acquir Immune Defic Syndr. 2012;60:77–82.CrossRefPubMed
22.
Rebeiro P, Althoff KN, Buchacz K, Gill J, Horberg M, Krentz H, et al. Retention among North American HIV-infected persons in clinical care, 2000–20008. J Acquir Immune Defic Syndr. 2013;62(3):356–62.CrossRefPubMedPubMedCentral
23.
Werb D, Mills EJ, Montaner JS, Wood E. Risk of resistance to highly active antiretroviral therapy among HIV-positive injecting drug users: a meta-analysis. Lancet Infect Dis. 2010;10:464–9.CrossRefPubMed
24.
Malta M, Strathdee SA, Magnanini MM, Bastos FI. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction. 2008;103:1242–57.CrossRefPubMed
25.
Roux P, Carrieri MP, Cohen J, Ravaux I, Poizot-Martin I, Dellamonica P, et al. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. Clin Infect Dis. 2009;49(9):1433–40.CrossRefPubMed
26.
Malee KM, Mellins CA, Huo Y, Tassiopoulos K, Smith R, Sirois PA, et al. Prevalence, incidence, and persistence of psychiatric and substance use disorders among mothers living with HIV. J Acquir Immune Defic Syndr. 2014;65(5):526–34.CrossRefPubMedPubMedCentral
27.
Rabkin JG, McElhinney MC, Ferrando SJ. Mood and substance use disorders in older adults with HIV/AIDS: Methodological issues and preliminary evidence. AIDS. 2004;18(Supplement #1):S43–8.CrossRefPubMed
28.
Rosenberg SD, Drake RE, Brunette MF, Wolford GL, Marsh BJ. Hepatitis C virus and HIV co-infection in people with severe mental illness and substance use disorders. AIDS. 2005;19(Supplement #3):S26–33.CrossRefPubMed
29.
Gaynes BN, Pence BW, Erron JJ, Miller WC. Prevalence and comorbidity of psychiatric diagnoses based on reference standard in an HIV+ patient population. Psychosom Med. 2008;70(4):505–11.CrossRefPubMedPubMedCentral
30.
Pence BW, Miller WC, Whetten K, Erron JJ, Gaynes BN. Prevalence of DSM-IV-defined mood, anxiety, and substance use disorders in an HIV clinic in the southeastern United Staes. J Acquir Immune Defic Syndr. 2006;42(3):298–306.CrossRefPubMed
31.
Atkinson JH, Grant I, Kennedy CJ, Richman DD, Spector SA, McCutchan JA. Prevalence of psychiatric disorders among men infected with human immunodeficiency virus: a controlled study. Arch Gen Psychiatry. 1988;45:859–64.CrossRefPubMed
32.
Dew MA, Becker JT, Sanchez J, Caldararo R, Lopez OL, Wess J, et al. Prevalence and predictors of depressive, anxiety, and substance use disorders in HIV-infected and uninfected men: a longitudinal evaluation. Psychol Med. 1997;27:395–409.CrossRefPubMed
33.
Perry S, Jacobsberg LB, Fishman B, Frances A, Bobo J, Jacobsberg BK. Psychiatric diagnosis before serological testing for the human immunodeficiency virus. Am J Psychiatry. 1990;147:89–93.CrossRefPubMed
34.
Catalan J, Klimes I, Bond A, Day A, Garrod A, Rizza C. The psychosocial impact of HIV infection in men with haemophilia: controlled investigation and factors associated with psychiatric morbidity. J Psychosom Res. 1992;36:409–16.CrossRefPubMed
35.
Catalan J, Klimes I, Day A, Garrod A, Bond A, Gallwey J. The psychosocial impact of HIV infection in gay men: a controlled investigation and factors associated with psychiatric morbidity. Br J Psychiatry. 1992;161:774–8.CrossRefPubMed
36.
Chuang HT, Jason GW, Pajurkova EM, Gill MJ. Psychiatric morbidity in patients with HIV infection. Can J Psychiatry. 1992;37:109–15.PubMed
37.
Williams JB, Rabkin JG, Remien RH, Gorman JM, Ehrhardt A. Multidisciplinary baseline assessment of homosexual mena with and without human immunodeficiency virus infection: standardized clinical assessment of current and lifetime psychopathology. Arch Gen Psychiatry. 1991;48:124–30.CrossRefPubMed
38.
Brown GR, Rundell JR, McManis SE, Kendall SN, Zachary R, Temoshok L. Prevalence of psychiatric disorders in early stages of HIV infection. Psychosom Med. 1992;54:588–601.CrossRefPubMed
39.
Lipsitz JD, Williams JB, Rabkin JG, Remien RH, Bradbury M, el Sadr W, et al. Psychopathology in male and female intravenous drug users with and without HIV infection. Am J Psychiatry. 1994;151:1662–8.CrossRefPubMed
40.
Rosenberger PH, Bornstein RA, Nasrallah HA, Para MF, Whitacre CC, Fass RJ, et al. Psychopathology in human immunodeficiency virus infection: lifetime and current assessment. Compr Psychiatry. 1993;34:150–8.CrossRefPubMed
41.
Maj M, Strarace F, Sartorius N. Mental disorders in HIV-I infection and AIDS. In: Sartorius N, Prilipko LL, editors. WHO expert series on biological psychiatry. Seattle: Hogrefe & Huber Publishers; 1993.
42.
Lyketsos CG, McHugh PR, Hanson A, Treisman GJ, Fishman M. Screening for psychiatric morbidity in a medical outpatient clinic for HIV infection: the need for a psychiatric presence. Int J Psychiatry Med. 1994;24:103–13.CrossRefPubMed
43.
Bix BC, Glosser G, Holmes W, Ballas C, Meritz M, Hutelmeyer C, et al. Relationship between psychiatric disease and neurological impairment in HIV seropositive individuals. J Int Neuropsychol Soc. 1995;1:581–8.CrossRefPubMed
44.
Johnson JG, Williams JB, Rabkin JG, Goetz R, Remien RH. Axis I psychiatric symptoms associated with HIV infection and personality disorder. Am J Psychiatry. 1995;152:551–4.CrossRefPubMed
45.
Summers J, Zisook S, Atkinson JH, Sciolla A, Whitehall W, Brown S, et al. Psychiatric morbidity associated with acquired immune deficiency syndrome-related grief resolution. J Nerv Ment Dis. 1995;183:384–9.CrossRefPubMed
46.
Sohler NL, Wong MD, Cunningham WE, Cabral H, Drainoni ML, Cunningham CO. Type and pattern of illicit drug use and access to health care services for HIV-infected people. AIDS Patient Care STDs. 2007;21(Supplement 1):S68–76.PubMed
47.
Rondinelli AJ, Ouellet LJ, Strathdee SA, Latka MH, Hudson SM, Hagan H, et al. Young adult injection drug users in the United States continue to practice HIV risk behaviors. Drug Alcohol Depend. 2009;104(1–2):167–74.CrossRefPubMed
48.
Engstrom M, Shibusawa T, El-Bassel N, Gilbert L. Age and HIV sexual risk among women in methadone treatment. AIDS Behav. 2011;15(1):103–13.CrossRefPubMed
49.
Strathdee SA, Sherman SG. The role of sexual transmission of HIV infection among injection and non-injection drug users. J Urban Health. 2003;80(Supplement 3):iii7–14.PubMedPubMedCentral
50.
Mimiaga MJ, Reisner SL, Grasso C, Crane HM, Safren SA, Kitahata MM, et al. Substance use among HIV-infected patients engaged in primary care in the United States: findings from the Centers for AIDS research network of integrated clinical systems cohort. Am J Public Health. 2013;103(8):1457–67.CrossRefPubMedPubMedCentral
51.
Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immmunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58(8):721–8.CrossRefPubMed
52.
Galvan FH, Bing EG, Fleishman JA, et al. The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: results from the HIV cost and services utilization study. J Stud Alcohol. 2002;63(2):179–86.CrossRefPubMed
53.
Grant BF, Goldstein RB, Saha TD, Chou C, Jung J, Zhang H, et al. Epidemiology of DSM-5 alcohol use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry. 2015;72(8):757–66.CrossRefPubMedPubMedCentral
54.
Grant BF, Saha TD, Ruan WJ, Goldstein RB, Chou SP, Jung J, et al. Epidemiology of DSM-5 drug use disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry. 2016;73(1):39–47.CrossRefPubMedPubMedCentral
55.
Kitahata MM, Rodriquez B, Haubrick R, Boswell S, Mathews WC, Lederman MM, et al. Cohort profile: The Centers for AIDS Research Network of Integrated Clinical Systems. Int J Epidemiol. 2008;37:948–55.CrossRefPubMedPubMedCentral
56.
Hughes MD. Initial treatment of HIV infection: randomized trials with clinical endpoints are still needed. J Infect Dis. 2006;194:542–4.CrossRefPubMed
57.
Dombrowski JC, Kitahata MM, Von Rompaey SE, Crane HM, Mugavero MJ, Eron JJ Jr, et al. High levels of antiretroviral use and viral suppression among persons in HIV care in the United States, 2010. JAIDS. 2013;63(3):299–306.PubMedPubMedCentral
58.
Humeniuk R, Ali R, Babor TF, Farrell M, Formigoni ML, Jittiwuikarn J, et al. Validation of the alcohol, smoking, and substance involvement screening test (ASSIST). Addiction. 2008;103(6):1039–47.CrossRefPubMed
59.
Dawson DA, Smith SM, Saha TD, Rubinsky AD, Grant BF. Comparative performance of the AUDIT-C in screening for DSM-IV and DSM-5 alcohol use disorders. Drug Alcohol Depend. 2012;126:384–8.CrossRefPubMedPubMedCentral
60.
Hubbard AE, Ahern J, Fleischer NL, Van der Laan M, Lippman SA, Jewell N, et al. To GEE or not to GEE: Comparing population average and mixed models for estimating the associations between neighborhood risk factors and health. Epidemiology. 2010;21:467–74.CrossRefPubMed
61.
Hasin DS, Kerridge BT, Saha TD, Huang B, Pickering RP, Smith SM, et al. Prevalence and correlates of DSM-5 cannabis use disorder, 2012–2013: findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III. Am J Psychiatry. 2016;173(6):588–99.CrossRefPubMed
62.
Grucza RA, Agrawal A, Krauss MJ, Cavazos-Rehg PA, Bierut LJ. Recent trends in the prevalence of marijuana use and associated disorders in the United States. JAMA Psychiatry. 2016;73(3):300–1.CrossRefPubMed
63.
Reif S, Pence BW, Hall I, Hu X, Whetten K, Wilson E. HIV diagnoses, prevalence, and outcomes in nine southern states. J Community Health. 2015;40(4):642–51.CrossRefPubMed
64.
Cima M, Parker RD, Ahmed Y, Cook S, Dykema S, Dukes K, et al. Cause of death in HIV-infected patients in South Carolina (2005–2013). Int J STD AIDS. 2016;27(1):25–32.CrossRefPubMed
65.
Schwarcz SK, Vu A, Hsu LC, Hessol NA. Changes in causes of death among persons with AIDS: San Francisco, California, 1996–2011. AIDS Patient Care STDs. 2014;28(10):517–23.CrossRefPubMed
66.
Remien RH, Goetz R, Rabkin JG, Williams JB, Bradbury M, Ehrhardt A, et al. Remission of substance use disorders: gay men in the first decade of AIDS. J Stud Alcohol. 1995;56:226–32.CrossRefPubMed
67.
Santos GM, Do T, Beck J, Makofane K, Arreola S, Pyun T, et al. Syndemic conditions associated with HIV risk in a global sample of men who have sex with men. Sex Transm Dis. 2014;90(3):250–3.CrossRef
68.
69.
Oldenburg CE, Perez-Brumer AG, Reisner SL. Poverty matters: contextualizing the syndemic condition of psychological factors and newly diagnosed HIV infection in the United States. AIDS. 2014;28(18):2763–9.CrossRefPubMedPubMedCentral
70.
Pence BW. The impact of mental health and traumatic life experiences on antiretroviral treatment outcomes for people living with HIV/AIDS. J Antimicrob Chemother. 2009;63:636–40.CrossRefPubMedPubMedCentral
71.
Kalichman SC, Sikkema KJ, DiFonzo K, Luke W, Austin J. Emotional adjustment in survivors of sexual assault living with HIV-AIDS. J Trauma Stress. 2002;15(4):286–96.CrossRef
72.
Parsons JT, Rosof E, Punzalan JC, Di Maria L. Integration of motivational interviewing and cognitive behavioral therapy to improve HIV medication adherence and reduce substance use among HIV-positive men and women: results of a pilot project. AIDS Patient Care STDs. 2005;19(1):31–9.CrossRefPubMed
73.
Safren SA, O’Cleirigh CM, Bullis JR, Otto MW, Stein MD, Pollack MH. Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected injection drug users: a randomized controlled trial. J Consult Clin Psychol. 2012;80(3):404–15.CrossRefPubMedPubMedCentral
74.
Petry NM, Weinstock J, Alessi SM, Lewis MW, Dieckhaus K. Group-based randomized trial of contingencies for health and abstinence in HIV patients. J Consult Clin Psychol. 2010;78(1):89–97.CrossRefPubMedPubMedCentral
75.
Rosen MI, Dieckhaus K, McMahon TJ, Valdes B, Petry N, Cramer JA, et al. Improved adherence with contingency management. AIDS Patient Care STDs. 2007;21(1):30–40.CrossRefPubMed
76.
Diiorio C, McCarty F, Resnicow K, McDonnell-Holstad M, Soet J, Yeager K, et al. Using motivational interviewing to promote adherence to antiretroviral medications: a randomized controlled study. AIDS Care. 2008;20(3):273–83.CrossRefPubMedPubMedCentral
77.
Williams AB, Fennie KP, Bova CA, Burgess JD, Danvers KA, Dieckhaus K. Home visits to improve adherence to highly active antiretroviral therapy: A randomized controlled trial. JAIDS. 2006;42(3):314–21.PubMed
78.
NIDA. Principles of drug addiction treatment: A research-based guide (3rd ed.). Services USDoHaH, editor2012.
Metadaten
Titel
Prevalence and Predictors of Substance Use Disorders Among HIV Care Enrollees in the United States
verfasst von
Bryan Hartzler
Julia C. Dombrowski
Heidi M. Crane
Joseph J. Eron
Elvin H. Geng
W. Christopher Mathews
Kenneth H. Mayer
Richard D. Moore
Michael J. Mugavero
Sonia Napravnik
Benigno Rodriguez
Dennis M. Donovan
Publikationsdatum
13.10.2016
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 4/2017
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-016-1584-6

Weitere Artikel der Ausgabe 4/2017

AIDS and Behavior 4/2017 Zur Ausgabe

Original Paper

A Hazard Analysis of Risk Factors of Mortality in Individuals Who Inject Drugs in Denver CO

Original Paper

Social Network Strategies to Address HIV Prevention and Treatment Continuum of Care Among At-risk and HIV-infected Substance Users: A Systematic Scoping Review

Original Paper

Trajectories of Marijuana Use among HIV-seropositive and HIV-seronegative MSM in the Multicenter AIDS Cohort Study (MACS), 1984–2013

Original Paper

The Information–Motivation–Behavioral Skills Model Revisited: A Network-Perspective Structural Equation Model Within a Public Sexually Transmitted Infection Clinic Sample of Hazardous Alcohol Users

Original Paper

The Relationship Between Methamphetamine Use, Sexual Sensation Seeking and Condomless Anal Intercourse Among Men Who Have Sex With Men in Vietnam: Results of a Community-Based, Cross-Sectional Study

Original Paper

A Moderated Mediation Model of HIV-Related Stigma, Depression, and Social Support on Health-Related Quality of Life among Incarcerated Malaysian Men with HIV and Opioid Dependence

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Parodontalbehandlung verbessert Prognose bei Katheterablation

18.04.2024 | Arterielle Hypertonie | Nachrichten

Antihypertensiva schützen auch alte Menschen noch vor Demenz

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

17.04.2024 | DGIM 2024 | Nachrichten

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise